The Octopus Value Investing

The Octopus Value Investing

Public companies research, value investig philosophy and much more.

PandoraPandora
+3+3
Q3 2024 Earnings Recap

Q3 2024 Earnings Recap

Earnings review compilation of Novo Nordisk, Pandora & Lonza AG

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#2 Schott Pharma AG - Quantitative Analysis

#2 Schott Pharma AG - Quantitative Analysis

Looking into the fundamentals of the pharma glass packaging leader

The Octopus Value Investing
The Octopus Value Investing
Schott Pharma AGSchott Pharma AG
#1 Schott Pharma - Qualitative Analysis

#1 Schott Pharma - Qualitative Analysis

Insights on the Pharmaceutical Glass Packaging Leader

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
Comparing the Pharmaceutical Glass Packaging Players

Comparing the Pharmaceutical Glass Packaging Players

Digging into Schott Pharma AG, Gerresheimer AG and Stevanato Group fundamentals

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
Novo Nordisk September 2024 recap

Novo Nordisk September 2024 recap

An hectic month for the Danish company

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
Understanding NASH/MASH

Understanding NASH/MASH

Uncovering the potential behind Novo Nordisk's optionality

The Octopus Value Investing
The Octopus Value Investing
Sectors in briefSectors in brief
#4 Sectors in Brief - Players in the Pharmaceutical Glass Packaging Segment

#4 Sectors in Brief - Players in the Pharmaceutical Glass Packaging Segment

Pinpointing Prominent Sector Players

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+1+1
Pandora A/S - H1 2024 Earnings Review

Pandora A/S - H1 2024 Earnings Review

The affordable luxury market defies pure luxury slowdown

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk - H1 2024 Earnings review

Novo Nordisk - H1 2024 Earnings review

More leader in the GLP-1 space than ever

The Octopus Value Investing
The Octopus Value Investing
Lonza Group AGLonza Group AG
+1+1
Lonza Group AG - H1 2024 Earnings Review

Lonza Group AG - H1 2024 Earnings Review

CDMO giant within expectations

The Octopus Value Investing
The Octopus Value Investing